Table 6.
Treatment of tumors with positive ALK translocation.
| PS ** | Median Age |
Regimen | Patients (n) |
Objective Response (CR + PR)/SD/PD; ORR (%) * | Median OS/MST *** | Study |
|---|---|---|---|---|---|---|
| ECOG PS 0–2 | 52 vs. 54 |
Crizotinib vs. Chemotherapy (Pemetrexed + Cisplatin/Carboplatin) |
343 | 128 (3 + 125)/29/8; 74% (95% CI 67–81%) vs. 77 (2 + 75)/63/21; 45% (95% CI 37–53%) (p < 0.001) |
HR 0.82 (95% CI 0.54–1.26, p = 0.36) (Immature results) |
2014, Solomon et al. [81] |
| NR (95% CI 45.8 m–NR) vs. 47.5 m (95% CI 32.2–NR) (HR 0.760, 95% CI 0.548–1.053, p = 0.0978) |
2018, Solomon et al. [82] | |||||
| ECOG PS 0–2 | 48 vs. 50 |
Crizotinib vs. Pemetrexed + Cisplatin/Carboplatin |
207 | 91 (3 + 88); 87.5% (95% CI 79.6–93.2%) vs. 47 (0 + 47); 45.6% (95% CI 35.8–55.7%) (p < 0.001) |
28.5 m (95% CI 26.4 m–NR) vs. 27.7 m (95% CI 23.9 m–NR) (HR 0.897, 95% CI 0.556–1.445, p = 0.327) |
2018, Wu et al. [80] |
| ECOG PS 0–2 | 53.8 vs. 56.3 |
Crizotinib vs. Alectinib |
303 | 114 (2 + 112)/24/NR; 75.5% (95% CI 67.8–82.1%) vs. 126 (6 + 120)/9/NR; 82.9% (95% CI 76.0–88.5%) (p = 0.09) |
HR = 0.76, 95% CI 0.48–1.20, p = 0.24 |
2017, Peters et al. [83] |
| ECOG PS 0–2 | 59.1 vs. 55.6 |
Lorlatinib vs. Crizotinib |
296 | 113 (4 + 109)/19/10; 76% (95% CI 68–83%) vs. 85 (0 + 85)/41/7; 58% (95% CI 49–66%) (OR 2.25, 95% CI 1.35–3.89) |
HR = 0.72, 95% CI 0.41–1.25 | 2020, Shaw et al. [84] |
* “Complete Response” (CR): Disappearance of all target lesions; “Partial Response” (PR): 30% or more decrease in the sum of diameter of target lesions compared to baseline diameter; “Stable Disease” (SD): Neither PR nor PD; “Progressive Disease” (PD): 20% or more increase in sum of diameter of target lesions compared to baseline diameter; “Objective response” = CR + PR [31]. ** “Performance Score” (PS): Eastern Cooperative Oncology Group (ECOG) PS, World Health Organization (WHO) PS, Karnofsky PS (KPS). *** “Overall Survival” (OS), “Median Survival Time” (MST).